Exploring the pharmacological mechanisms and therapeutic implications of galangin against neurological disorders
- PMID: 40540149
- DOI: 10.1007/s43440-025-00756-z
Exploring the pharmacological mechanisms and therapeutic implications of galangin against neurological disorders
Abstract
Neurological disorders represent a leading cause of mortality and disability worldwide, encompassing a broad spectrum of prevalent conditions such as Alzheimer's disease, epilepsy, and stroke. In recent years, natural compounds have garnered increasing attention as potential therapeutic and preventive agents for neurological disorders. Galangin, a naturally occurring flavonoid primarily derived from Alpinia officinarum Hance, exhibits diverse biological properties, including notable neuroprotective, anti-tumor, and anti-inflammatory effects. Emerging evidence indicates that galangin exerts significant neuroprotective effects through multiple mechanisms. This review systematically summarizes the in vivo metabolism and pharmacokinetics of galangin, elucidates its mechanism of action, and highlights recent advances in its application for neurological disorders. Furthermore, the prospect of nanodrug carriers for enhancing the therapeutic efficacy of galangin is explored. Additionally, this review addresses the current research limitations and outlines future research directions to provide a theoretical foundation for its clinical application in neurological disorders. Collectively, the findings underscore the extensive pharmacological properties and therapeutic potential of galangin, highlighting its promise as a novel candidate for the treatment and prevention of neurological disorders and warranting further in-depth investigation and development.
Keywords: Galangin; Molecular mechanisms; Natural compound; Neuroinflammation; Neurological disorders.
© 2025. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Similar articles
-
Excitatory amino acid antagonists for acute stroke.Cochrane Database Syst Rev. 2003;2003(3):CD001244. doi: 10.1002/14651858.CD001244. Cochrane Database Syst Rev. 2003. PMID: 12917902 Free PMC article.
-
Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.Cochrane Database Syst Rev. 2017 Feb 27;2(2):CD001911. doi: 10.1002/14651858.CD001911.pub3. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 Jul 18;7:CD001911. doi: 10.1002/14651858.CD001911.pub4. PMID: 28240353 Free PMC article. Updated.
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Repetitive transcranial magnetic stimulation (rTMS) for multiple neurological conditions in rodent animal models: A systematic review.Neurochem Int. 2022 Jul;157:105356. doi: 10.1016/j.neuint.2022.105356. Epub 2022 May 2. Neurochem Int. 2022. PMID: 35513205
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Grosso C, Santos M, Barroso MF. From plants to Psycho-Neurology: unravelling the therapeutic benefits of bioactive compounds in brain disorders. Antioxid (Basel). 2023;12(8).
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources